Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
- Conditions
- Interventions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02533323
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT02393859
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02359162
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
- Conditions
- Adult T Acute Lymphoblastic LeukemiaAnn Arbor Stage II Adult Lymphoblastic LymphomaAnn Arbor Stage II Childhood Lymphoblastic LymphomaAnn Arbor Stage III Adult Lymphoblastic LymphomaAnn Arbor Stage III Childhood Lymphoblastic LymphomaAnn Arbor Stage IV Adult Lymphoblastic LymphomaAnn Arbor Stage IV Childhood Lymphoblastic LymphomaChildhood T Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: BortezomibDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: DoxorubicinDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine SulfateDrug: Vincristine
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 847
- Registration Number
- NCT02112916
- Locations
- 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BlinatumomabDrug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneOther: Pharmacological StudyDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideRadiation: Radiation TherapyDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 264
- Registration Number
- NCT02085655
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideDrug: Leucovorin CalciumProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: PrednisoneBiological: RituximabDrug: VincristineDrug: Vincristine SulfateProcedure: X-Ray Imaging
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 488
- Registration Number
- NCT02003222
- Locations
- 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Banner McKee Medical Center, Loveland, Colorado, United States
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT01991158
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.